Core Viewpoint - Zhejiang Haishen Pharmaceutical Co., Ltd. has completed the registration of the reserved grant for the 2024 restricted stock incentive plan, which includes the approval processes and details regarding the stock grants [1][2][3]. Summary by Sections Approval Procedures - The company held a board meeting on September 12, 2024, to approve the incentive plan and related documents, with reports from legal and independent financial advisors [1]. - The supervisory board also approved the plan and the list of initial grant recipients on September 12, 2024 [2]. - A temporary shareholders' meeting on September 30, 2024, further approved the incentive plan and related matters [3]. Reserved Grant Registration Details - The reserved grant date is set for September 11, 2025, with the listing date for the restricted stock on October 30, 2025 [4]. - A total of 424,760 shares will be granted, accounting for 0.2796% of the company's total equity at the time of the reserved grant [4]. - The grant price is set at 8.43 CNY per share, with 31 individuals receiving the grants [4][8][9]. Conditions and Restrictions - The incentive plan has a maximum validity period of 60 months from the completion of the initial grant registration [12]. - Different lock-up periods apply, with a minimum of 12 to 24 months for the reserved grants [13]. - The conditions for lifting the lock-up include the company's financial performance and the individual performance of the recipients [16][18]. Financial Impact - The total share capital will increase from 151,926,440 shares to 152,351,200 shares following the grant registration [21]. - The diluted earnings per share for 2024 is projected to be 0.80 CNY [22]. - Funds raised from the stock grants will be used to supplement working capital [23]. Compliance and Reporting - The company has confirmed that the stock grant does not affect its compliance with listing conditions and that the controlling shareholders' stakes remain unchanged [21]. - A verification report from the accounting firm confirms the funds received from the grant recipients [20].
浙江海森药业股份有限公司关于2024年限制性股票激励计划预留授予登记完成的公告